Ran across an article discussing nuerotopic factor
Post# of 30028
Posted On: 08/30/2014 7:17:31 PM
Ran across an article discussing nuerotopic factors and came across something interesting.
Although there are strong rationales suggesting that increasing supply of neurotrophins to degenerating neurons may be a potent way to restore neuronal function in neurodegenerative conditions, delivering neurotrophins into the brain has proven to be a non-trivial matter. Notoriously, CNS diseases are difficult to treat due to the presence of the blood brain barrier (BBB) that makes it almost impossible for large proteins and complex compounds to cross from the blood into the brain. In addition, the cortical and subcortical circuits of the brain are interconnected resulting in crosstalk among multiple regions, so coming up with a treatment strategy that selectively targets affected neurons only, but not those unaffected ones, is a great challenge that has to be carefully considered. To further compound these issues, neurotrophins are relatively large, polar molecules that cannot readily cross BBB and therefore must be administered directly into the central nervous system (CNS). Indeed, all current delivery strategies involve invasive procedures as discussed below.
Wouldn't this problem be solved by Lympro by narrowing the bio makers for certain diseases? It seems Lympro has bridge the gap in determination of how to target specific neurons that are being affected by the disease.
http://www.translationalneurodegeneration.com/content/1/1/14
Although there are strong rationales suggesting that increasing supply of neurotrophins to degenerating neurons may be a potent way to restore neuronal function in neurodegenerative conditions, delivering neurotrophins into the brain has proven to be a non-trivial matter. Notoriously, CNS diseases are difficult to treat due to the presence of the blood brain barrier (BBB) that makes it almost impossible for large proteins and complex compounds to cross from the blood into the brain. In addition, the cortical and subcortical circuits of the brain are interconnected resulting in crosstalk among multiple regions, so coming up with a treatment strategy that selectively targets affected neurons only, but not those unaffected ones, is a great challenge that has to be carefully considered. To further compound these issues, neurotrophins are relatively large, polar molecules that cannot readily cross BBB and therefore must be administered directly into the central nervous system (CNS). Indeed, all current delivery strategies involve invasive procedures as discussed below.
Wouldn't this problem be solved by Lympro by narrowing the bio makers for certain diseases? It seems Lympro has bridge the gap in determination of how to target specific neurons that are being affected by the disease.
http://www.translationalneurodegeneration.com/content/1/1/14
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼